Santa Monica, CA, May 01, 2018 (GLOBE NEWSWIRE) --
BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical
signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace,
today announced that the Company closed a private placement with proceeds of $4,789,510. Combined with the closing of our February
2018 placement, the Company has raised $6,289,510 in 2018.
The Company issued 3,193,004 common shares at a price of $1.50 per share and a half warrant with a 3-year expiration at a cash
exercise price of $1.75.
BioSig placed this transaction largely with existing shareholders while welcoming a number of new long-term accredited
investors. This was the first financing completed without registration rights, further demonstrating appetite for longer-term
investment in the Company.
“Support from long-term shareholders is the key to sustaining innovation. It allows us to focus on the upcoming milestones as we
progress towards targeted commercial launch,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. “This
raise also allows us to commence our uplisting activities to a U.S. based national trading exchange such as the Nasdaq or NYSE
stock markets – a major milestone for 2018.”
About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to
improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of
Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been
developed to address an unmet need in a large and growing market.
The Company’s first product, PURE EP(TM) System, is a novel cardiac signal acquisition and display system which is engineered to
assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates
and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly
arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and
is working toward FDA 510(k) clearance for the PURE EP System.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words.
Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various
known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified
and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our
product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed
information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in
the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s
website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events or otherwise.
Contact: Natasha Russkina BioSig Technologies, Inc. VP Business Development & Corporate Finance nrusskina@biosigtech.com +41 (0) 76 823 7527
